LEXINGTON, Mass. AND MUNICH, Germany,– RainDance Technologies, Inc., the Digital Biology™ Company, today announced that MLL Munich Leukemia Laboratory (MLL) has purchased the company’s ThunderStorm™ System and consumables to process an initial 2,000 samples for use in the identification of prognostically relevant molecular mutations associated with Acute Myeloid Leukemia (AML) and other myeloid malignancies. Additionally, […]

Gaithersburg, Maryland and SEOUL, Korea, – Seegene Inc., (096530.KQ), a leading developer of multiplex molecular diagnostic technologies and tests, today announced the development and commercialization of the first molecular assay for the detection, genotyping and quantification of nineteen high-risk and nine low-risk genotypes of the Human Papilloma virus (HPV). Seegene’s breakthrough new test, QuantPlex(TM) HPV28 […]

BREA, CALIF. — Beckman Coulter, Inc., the leader in prostate cancer diagnostics, announces Premarket Approval (PMA) from the U.S. Food and Drug Administration (FDA) for the Prostate Health Index (phi), a simple, non-invasive blood test that is 2.5 times more specific in detecting prostate cancer1 than PSA (prostate-specific antigen) in patients with PSA values in […]

Agilent Technologies Inc. (NYSE: A) today announced that its acquisition of cancer diagnostics company Dako has been completed. Agilent, which paid $2.2 billion in cash for Dako (on a debt-free basis), expects the acquisition to help strengthen Agilent’s position in life sciences, with a focus on product development to help in the fight against cancer. […]

LEXINGTON, MA – Predictive Biosciences today announced the introduction of next generation sequencing (NGS) into the company’s CertNDx™ bladder cancer tests. The company has developed a new, highly sensitive non-invasive urine-based assay that uses NGS to analyze FGFR3 mutations for bladder cancer detection, which demonstrated a significant improvement in sensitivity over the qPCR method currently […]

Austin, Texas – Asuragen, Inc. announced today that it has granted BD (Becton, Dickinson and Company), a global medical technology company, non-exclusive worldwide rights to incorporate Armored RNA® technology into its in vitro molecular diagnostics products. Under the terms of the Agreement, Asuragen will develop and supply reagents for BD Diagnostics in Asuragen’s cGMP manufacturing […]

BEDFORD, Mass. and SAN DIEGO, Calif., — Hologic, Inc. (Hologic) (NASDAQ: HOLX) and Gen-Probe Incorporated (Gen-Probe) (NASDAQ: GPRO) today announced that, in connection with Hologic’s proposed acquisition of Gen-Probe, the initial 30-day waiting period required under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, expired without a request for additional information from the Federal […]

Niel,– Multiplicom, a molecular diagnostics company specializing in innovative molecular genetics tests based on massive parallel sequencing, has received CE/IVD mark accreditation for its first-in-class BRCA MASTR Dx test. The test identifies mutations in the coding regions of the BRCA 1&2 genes in individuals with increased risk for breast, ovarian and/or related cancers. The test […]

Gaithersburg, Maryland and SEOUL, Korea, – Seegene Inc., (096530.KQ), a leading developer of multiplex molecular diagnostic technologies and tests, today announced the development of a new molecular assay for the quantification of twenty-onerespiratory viral pathogens associated with respiratory disease. QuantPlex RV-16 Assay will give physicians the specific information needed to guide patient treatment decisions, and […]

SUNNYVALE, Calif., — Cepheid (Nasdaq: CPHD) today welcomed UNITAID’s announcement that it has approved funding of $30 million to scale up access to the “ground-breaking” Xpert MTB/RIF in high burden developing countries (HBDC). According to UNITAID, the funds will be used to roll out Xpert-based programs in around 20 countries, in addition to supporting a […]